Geptanolimab (CBT-501) is a humanized IgG4k моноклональный антитело against programmed death-1 (PD-1). Siplizumab inhibits the связывание of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer.
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.